INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 38 filers reported holding INOZYME PHARMA INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,559,557 | +22.9% | 2,276,085 | +63.1% | 0.00% | – |
| Q2 2023 | $7,775,218 | +2.2% | 1,395,910 | +5.1% | 0.00% | – |
| Q1 2023 | $7,611,102 | +439.5% | 1,328,290 | -1.1% | 0.00% | – |
| Q4 2022 | $1,410,803 | -60.8% | 1,343,622 | +0.0% | 0.00% | – |
| Q3 2022 | $3,599,000 | -44.3% | 1,343,063 | -0.8% | 0.00% | – |
| Q2 2022 | $6,460,000 | +222.5% | 1,354,216 | +176.6% | 0.00% | – |
| Q1 2022 | $2,003,000 | -39.9% | 489,613 | +0.2% | 0.00% | – |
| Q4 2021 | $3,333,000 | -53.0% | 488,719 | -20.0% | 0.00% | – |
| Q3 2021 | $7,084,000 | +24.0% | 611,185 | +82.3% | 0.00% | – |
| Q2 2021 | $5,713,000 | -15.4% | 335,286 | -1.7% | 0.00% | – |
| Q1 2021 | $6,751,000 | +5.8% | 340,964 | +10.3% | 0.00% | – |
| Q4 2020 | $6,380,000 | -18.3% | 309,114 | +4.1% | 0.00% | – |
| Q3 2020 | $7,809,000 | – | 297,037 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $18,441,000 | 6.52% |
| CHI Advisors LLC | 920,264 | $10,666,000 | 3.11% |
| Sofinnova Investments, Inc. | 2,028,308 | $23,508,000 | 1.39% |
| MPM BioImpact LLC | 320,724 | $3,717,000 | 0.58% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,344,786 | $27,176,000 | 0.53% |
| NEA Management Company, LLC | 2,444,379 | $28,330,000 | 0.34% |
| Rock Springs Capital Management LP | 850,015 | $9,852,000 | 0.21% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 986,400 | $11,432,000 | 0.19% |
| Overbrook Management Corp | 16,726 | $194,000 | 0.04% |
| Orbimed Advisors | 294,000 | $3,407,000 | 0.04% |